Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mereo Biopharma Group Plc ADR
(NQ:
MREO
)
3.270
+0.170 (+5.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mereo Biopharma Group Plc ADR
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
January 08, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
October 23, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023
From
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via
GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
October 09, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
September 07, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
July 06, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Mereo BioPharma to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
May 23, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 08, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
May 05, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
April 13, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
March 28, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
March 21, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 08, 2023
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 08, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
November 02, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
October 28, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
October 24, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
October 21, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan
October 18, 2022
From
Rubric Capital Management LP
Via
Business Wire
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
October 18, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
October 17, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
October 03, 2022
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five
October 03, 2022
From
Rubric Capital Management LP
Via
Business Wire
Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders
September 14, 2022
From
Rubric Capital Management LP
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.